EXAGEN INC.
XGN · XNASCIK 1274737fmd_1P5V5YXCDGYZB65W5FSERSPGJ0Services · Services-Medical LaboratoriesTemplate: Standard
Coverage: Jan 01, 2018 to Sep 30, 2026, 35 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | 32 | 40 | 42 | 48 | 46 | 53 | 56 | 67 |
| Cost of revenue | 15 | 19 | 17 | 21 | 24 | 23 | 23 | 28 |
| Gross profit | 17 | 22 | 25 | 28 | 21 | 29 | 33 | 39 |
| Research and development | 2 | 2 | 4 | 7 | 10 | 5 | 5 | 6 |
| Selling, general and administrative | 20 | 29 | 37 | 45 | 52 | 47 | 41 | 47 |
| Operating income | (5) | (9) | (15) | (24) | (46) | (23) | (14) | (14) |
| Interest expense | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 4 |
| Interest and investment income | – | – | – | – | – | 2 | 1 | 0 |
| Other non-operating income (expense) | 0 | 1 | 1 | 0 | – | – | – | – |
| Income tax expense | 0 | 0 | (0) | 0 | (0) | 0 | 0 | 0 |
| Net income | (8) | (12) | (17) | (27) | (47) | (24) | (15) | (20) |
| Net income to common shareholders | (18) | (30) | (17) | – | – | – | – | – |